In the larger picture, the fight against HIV has been a triumph of modern medicine. A patient diagnosed with HIV in the 1980s had a remaining life expectancy of 1 to 2 years. In 2023, they can expect to live another half century. But so far, an HIV vaccine has remained elusive. In the newest phase III failure, Janssen Pharmaceutical Cos. of Johnson & Johnson closed down its Mosaico trial more than a year ahead of schedule, following a data and safety monitoring board’s (DSMB) report saying the study was not expected to hit its primary endpoint. Read More
Researchers led by Congcong He at Northwestern University have found that exercise caused contracting muscles to secrete a glycoprotein called fibronectin (FN1) that induced autophagy in the liver which, in turn, drove insulin sensitization. They reported their findings online in Cell Metabolism on Feb. 21, 2023. He is an assistant professor of cell and developmental biology at the Feinberg School of Medicine. Read More
Targeted protein degradation (TPD) has emerged as a therapeutic strategy to overcome intractable disease-causing proteins, and hydrophobic... Read More
Adenosine deaminase acting on RNA1 (ADAR1) p150 is an inflammation-induced protein isoform of ADAR1 involved in immune silencing, metastasis... Read More
Medulloblastomas (MBs) are the most common malignant brain tumors in pediatric patients. Among the different types of MBs, those driven by MYC amplification present the worst prognosis. In a recent study published in Nature Communications, scientists from Cincinnati Children's Hospital Medical Center and collaborators investigated the molecular and genetic events triggering MYC amplification and malignant transformation in MBs, which remained previously unclear. Read More
Researchers at Cincinnati Children's Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have disclosed IL-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders. Read More
Hangzhou Healzen Therapeutics Co. Ltd. has synthesized programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders. Read More
Microglial cells (MGs) are resident immune cells in the brain, which play a key role in the acute response and chronic recovery to stroke. Investigators at the University of Texas Health Science Center Houston aimed to evaluate MG transcriptomic response to stroke in mouse brain. Read More
Carna Biosciences Inc. and Sumitomo Pharma Co. Ltd. have identified dual-specificity tyrosine-(Y)-phosphorylation regulated kinase (DYRK) inhibitors reported to be useful for the treatment of cancer, depression, epilepsy, dementia, psychosis, thyroid and gastrointestinal disorders, among others. Read More
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer. Read More
Nuclear body protein SP140 is mainly expressed on immune cells such as B and T cells, monocytes or dendritic cells and they are activated by interferon and regulated upon cellular stress, such as during viral infections. Read More
